Institut Pasteur Korea - Advanced Biomedical Research Lab.

Home >Research Discovery>Discovery Biology

Advanced Biomedical Research Lab

Introduction of group leader

Haengran Seo, Ph.D.
Doctorate: Korea University, Korea (2008)
Post-Doctorate: Korea Institute of Radiological and Medical Sciences, Korea (2008-2010)
Post-Doctorate : Institut Pasteur Korea (2010-2012)
Head, Cancer Biology Research Laboratory, Institut Pasteur Korea (2012-2021)
Head, Advanced Biomedical Research Laboratory, Institut Pasteur Korea (2021-present)

Office phone: +82-31-8018-8300
Office location: R3.03

Research Interests

The Advanced Biomedical Research Laboratory’s area of expertise is liver cancer. Despite liver cancer being the sixth most frequent malignant tumor cancer globally (2012. CDC[1]), and the second leading cause of cancer-related deaths (2012. CDC[1]), it has been difficult to develop effective targeted therapies. There are only a few ways to treat liver cancer currently and only 10-20% of liver cancers can be removed surgically [2], therefore more innovative and novel approaches must be taken to improve treatment options.

To overcome the limitations of existing liver cancer therapies, CBRL takes a holistic view of tumors, constructing a 3-dimensional (3D) tumor microenvironment in vitro to fully understand tumor development, progression, chemo-resistance and treatment response which can be used as a platform for anti-cancer drug discovery, improving personalized cancer therapy.
Our present activity focuses on:
Establishing 3D tumor microenvironment in vitro
Investigating reciprocal crosstalk between the tumor and tumor microenvironment to reveal new information on infrastructure that supports tumor existence
Examining new molecular mechanism(s) involved in anti-liver cancer drug resistance
Establishing 3D tumor microenvironment platform for anti-liver cancer drug discovery
Discovering new biomarker(s) for liver cancer early diagnosis and novel target(s) for liver cancer therapy
Reference (Source):
1) CDC : Centers for Disease Control and Prevention
2) Hepatocellular carcinoma. MedlinePlus, Medical Encyclopedia and wikipedia

Recent Publications

Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model
Yeonhwa Song, Sanghwa Kim, Jinyeong Heo, David Shum, Su-Yeon Lee, Minji Lee, A-Ram Kim, Haeng Ran Seo
Sci Rep. 2021 May 25;11(1):10931

Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma
Sanghwa Kim, Minji Lee, Yeonhwa Song, Su-Yeon Lee, Inhee Choi, I-Seul Park, Jiho Kim, Jin-sun Kim, Kang mo Kim, Haeng Ran Seo
J. Exp. Clin. Cancer Res. (2021) 40:127

Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma
Yeonhwa Song, Sanghwa Kim, Hyeryon Lee, Joo Hwan No, Hyung Chul Ryu, Jason Kim, Jee Woong Lim, Moonhee Kim, Inhee Choi, and Haeng Ran Seo
Cancers (Basel). 2020 May; 12(5): 1193

Inhibitors of Na+/K+ ATPase exhibit antitumor effects on multicellular tumor spheroids of hepatocellular carcinoma
Yeonhwa Song, Su-Yeon Lee, Sanghwa Kim, Inhee Choi, Se-Hyuk Kim, David Shum, Jinyeong Heo, A-Ram Kim, Kang Mo Kim, Haeng Ran Seo
Sci Rep. 2020 Mar 24;10(1):5318

GSK-3 beta regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models
Se-Hyuk Kim, Yeonhwa Song, Haeng Ran Seo
J. Exp. Clin. Cancer Res. 2019 Feb 1;38(1):46